General News

Paxil Birth Defect Litigation - First Trial A Bust For Glaxo

By (about the author)     Permalink       (Page 5 of 5 pages)
Related Topic(s): ; ; ; , Add Tags Add to My Group(s)

View Ratings | Rate It

opednews.com Headlined to H4 2/18/10

During the trial, it came out that the FDA employee who signed off on a Category B rating, a Dr Evoniuk, went on to work for Glaxo in the marketing department that sells Paxil.

A former FDA scientist, Doctor Suzanne Parisian, also testified as an expert for the plaintiffs. Adam Peavy, of the Houston firm of Bailey, Perrin and Bailey, handled her testimony.

Parisian testified that Doctor Sparenborg, a toxicologist at the FDA, raised a concern that there might be a problem with Paxil being a teratogen in 1995, when the pregnancy rating was changed from Category B to Category C.

When the company applied for approval of Paxil to treat Panic Disorder, Sparenborg suggested that the company "do a cross-fostering study to see if the adverse effect is occurring before the baby is born or after the baby is born," she said.

"Cross-fostering is ... taking rats from treated mothers and putting them with a control rat that didn't receive the drug," she explained to the jury. "So you are looking at whether the effect in the rat that could be produced in the pup was due to the mother herself or if it was something that was due to the rat before it was born."

The FDA asked Glaxo to submit a protocol for the study, "for our concurrence," before initiating it. But to her knowledge, Parisian said, Glaxo never submitted a protocol and never conducted a cross-fostering study.


She testified that such a study "would have helped to address where the negative effects were coming from."

While Parisian was testifying, the jury was shown the label for Paxil as it appeared in early January 2005, when Lyam's mother was prescribed Paxil as a Category C drug, with a discussion about the death of rat pups that implied the pups only died if the mothers received Paxil during the last trimester.

The label stated: "in rats there was an increase of pup deaths during the first four-day lactation when dosing occurred during the last trimester."

Parisian told the jury that there were deaths in pups born to mothers exposed to Paxil in the first and second trimesters as well. This Paxil label "implies to a physician that the animal studies support that it is safe to give the drug to the woman in the first and second trimester; that you need to be concerned about it in the last trimester," she testified.

The label is saying "there is no evidence of teratogenic effects," she said, "that means that it's safe for the first trimester. "

"If a physician were to read this, they would be more likely to prescribe it early in pregnancy," she told the jury.

Next Page  1  |  2  |  3  |  4  |  5

 

Evelyn Pringle is an investigative journalist and researcher focused on exposing corruption in government and corporate America.

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon

The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact Author Contact Editor View Authors' Articles
Related Topic(s): ; ; ; , Add Tags

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Tracking the American Epidemic of Mental Illness - Part II

Tracking the American Epidemic of Mental Illness - Part I

The Rise and Fall of Provigil -" Part I

The Rise and Fall of Provigil - Part II

Psychiatric Drugging of Infants and Toddlers in the US - Part I

Tracking the American Epidemic of Mental Illness - Part III

Comments

The time limit for entering new comments on this article has expired.

This limit can be removed. Our paid membership program is designed to give you many benefits, such as removing this time limit. To learn more, please click here.

Comments: Expand   Shrink   Hide  
1 people are discussing this page, with 1 comments
To view all comments:
Expand Comments
(Or you can set your preferences to show all comments, always)
If the evidence discussed in this article is corre... by kanawah on Thursday, Feb 18, 2010 at 7:59:29 PM